China-based Shanghai Thederma Pharmaceuticals Co., Ltd has reportedly raised RMB 100 million (USD 14.35 million) in a Series A financing round. The round was led by Bainuo Capital, with participation from existing investor Hankang Capital. The proceeds will be used to support research and development and clinical studies for multiple autoimmune inflammatory disease therapies targeting aryl hydrocarbon receptors (AhR).
AhR and Its Role in Disease
AhR is a ligand-activated transcription factor that can sense a variety of endogenous and exogenous molecules and affect biological effects. It is an important immune regulator in the human body, expressed in various tissues, particularly in the epidermis and mucous membrane. AhR-targeted therapies have applications in the digestive system, respiratory system, ophthalmology, and dermatology, addressing autoimmune inflammatory diseases.
Company and Leadership
Thederma Pharma, focused on the development of AhR-related autoimmune inflammatory disease therapies, is led by Dr. Chen Genghui, who co-discovered the world’s first AhR-targeted external drug. This first-in-class drug has been approved in both China and the United States, highlighting Thederma’s innovative approach to treating autoimmune conditions.
Significance of the Financing
This Series A financing round provides Thederma Pharmaceuticals with the necessary resources to advance its pipeline of AhR-targeted therapies. By investing in R&D and clinical studies, the company aims to bring innovative and effective treatments to patients suffering from autoimmune inflammatory diseases, potentially improving their quality of life.-Fineline Info & Tech
